Vyome Holdings, Inc. (HIND) Investor Relations Documents

Vyome Holdings, Inc. (HIND) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-02-01. Read in-app with summaries. First-party data.

VT-1953 in Treating Symptoms of Malignant Fungating Wounds (MFW): Vyome Holdings reports positive Phase 2 results for VT-1953 in treating malignant fungating wounds, showing statistically significant improvements in malodor and pain.

Investor relations documents — source: company IR site

Published	Type	Document
2026-07-01	Press release	Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
2026-05-28	Press release	Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
2026-05-12	Press release	Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
2026-04-22	Press release	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
2026-04-06	Press release	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
2026-03-26	Press release	Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
2026-02-18	Press release	Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunit
2026-02-11	Press release	Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
2026-02-02	Press release	Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
2026-02-01	Presentation	VT-1953 in Treating Symptoms of Malignant Fungating Wounds (MFW)

HIND overview · HIND earnings · HIND financials · HIND KPIs · HIND ownership · HIND peers · HIND filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.